References for Flavay® and Flavay Plus®

The health benefits and safety of Flavay® are documented by a library of research, patents, and validated by the French Ministry of Health.
Flavay Flavay Plus

Clinical Strength
Validated by Patents and Clinical Trials

Buy Now Call Now
  • 1. Masquelier J. Plant extract with a proanthocyanidins content as a therapeutic agent having radical scavenging effect and use thereof. U.S. Patent No. 4,698,360, 1987.
  • 2. Masquelier J. A lifetime devoted to OPC and pycnogenols. Alfa Omega Editrice, Pub. 1996.
  • 3. Schwitters B. Masquelier, J. OPC in practice. Alfa Omega Editrice, Pub., 1995.
  • 4. Schwitters B. Dr. Masquelier's mark on health. Alfa Omega Editrice, Pub., 2004.
  • 5. Kilham C. Masquelier, J. OPC: The miracle antioxidant. Keats Pub., Inc. 1997.
  • 6. Masquelier J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Natural Products as Medicinal Agents, Vol. 1, Hippokrates Verlag, Stuttgart, pp. 243-256, 1981.
  • 7. Passwater RA. The antioxidants: the nutrients that guard your body. Keats Pub., Inc. 1985.
  • 8. Passwater RA, et al. Pycnogenol super 'protector' nutrient. Keats Pub., Inc. 1994.
  • 9. Barilla J, et al. The nutrition superbook: volume 1: the antioxidants. Keats Pub., Inc. 1995.
  • 10. Packer, L, et al. The antioxidant miracle: your complete plan. John Wiley & Sons, Inc. 1999.
  • 11. Lieberman, S, et al. The real vitamin & mineral book: going beyond the RDA. Avery Pub. 1990.
  • 12. Mindell, E, et al. Earl Mindell's vitamin bible for the 21st century. Warner Books, Inc. 1999.
  • 13. Braverman, E, et al. The healing nutrients within: in facts, findings and new research. Keats, 1987.
  • 14. Lombard, J. (board certified neurologist), et al. The brain wellness plan - breakthrough medical, nutritional and immune-boosting therapies to prevent and treat depression, alzheimer's disease, chronic fatigue syndrome, attention deficit disorder, multiple sclerosis, parkinson's disease, lou gehrig's disease. Kensington Pub. Corp. 1998.
  • 15. Carper J. Miracle cures: dramatic new scientific discoveries revealing the healing powers of herbs, vitamins, and other natural remedies. HarperCollins Pub., 1998.
  • 16. Philpott, WH, et al. Brain Allergies: The Psychonutrient Connection, Keats Pub., 1980.
  • 17. Journal of the American Medical Association report on meeting of experts on the subject of food and behavior. Conclusions from this conference were summarized as follows: dietary pharmacology is no longer at the fringe of medicine...foods do affect behavior. Foods do affect the brain. JAMA 254:4, Dec. 27, 1985.
  • 18. Masquelier J, et al. Stabilization of collagen by procyanidolic oligomers. Acta Therap 7:101-5, 1981.
  • 19. Tixier, J.M, et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Pharmacol, 33:3933-9, 1984.
  • 20. Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides. A Vie Medical 12:1969.
  • 21. Laparra, J, et al. Etude pharmaco-cinetique des oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
  • 22. Laparra, J, et al. Etude pharmacocinetique des oligomeres flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
  • 23. Robert AM, et al. Etude de l’action des oligomeres procyanidoliques sur des cellules mesenchymateuses en culture. II l’attachment des fibres elastiques aux cellules. (Study of the effect of procyanidolic oligomers on mesenchymal cells in culture II. Attachment of elastic fibers to the cells.) Pat Biol (30)6:601-7, 1990.
  • 24. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
  • 25. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
  • 26. Porter, Lawrence J. Wong Rosalind Y. Chan, Bock G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its heterocyclic ring conformation in solution and the solid state. Journal of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
  • 27. Masquelier, J. Proanthocyanidins et radicaux libres (Radical scavenger effect of proanthocyanidins), 1985.
  • 28. Uchida S, et al. Condensed tannins scavenge active oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
  • 29. Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990. pp. 2499-2504.
  • 30. Da Silva, R. et. al. Radical scavenger capacity of different procyanidins from grape seeds. Presented at a symposium, “Free radicals in biotechnology and medicine.” Royal Society Of Chemistry, London January 1990, pp. 79-80.
  • 31. Bauman J, et al. “Hemmung der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
  • 32. Facino RM, et al. Free radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung, 44: 592-601, 1994.
  • 33. Kuttan R, et al. Collagen treated with catechin becomes resistant to the action of mammalian collagenase. Experientia, 37: 221-223, 1981.
  • 34. Masquelier J. Procyanidolic oligomers. J Parums Cosm Arom, 95: 89-97, 1990.
  • 35. Kakegawa H, et al. Inhibitory effects of tannins on hyaluronidase activation and the degranulation from rat mesentry mast cells. Chem. Pharm. Bull. 33(11)5079, 1985.
  • 36. Harmand MF, et al. The fate of total flavanolic oligomers extracted from ‘vitus vinifera l.’ in the rat. European Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
  • 37. Delrieu P, et al. Free-radical scavenging activity of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo and in vitro study. Cosmetology Department & S Biovectors, Ramonville St. Agne France. pp. 1-9.
  • 38. Meunier MT, et al. Inhibition of angiotensin i converting enzyme by flavanolic compounds: in vitro and in vivo studies. Planta Medica, May 26, 1986. pp. 12-15.
  • 39. Kim J, et al. Effect of select antioxidants on malondialdehyde modification of proteins. Nutrition, Nov-Dec;16(11-12):1079-81, 2000.
  • 40. Barbier A, et al. Activite angioprotectrice des oligomeres procyanidolques chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40. (1989)
  • 41. Dubos C, et al. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l’action d’une substance capillaro-toxique chez des personnes agees--action benefique d’un agnet actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980. pp. 302-305.
  • 42. Dartenuc JY, et al. Resistance capillaire en geriatrie etude d’un microangioprotecteur-Endotelon. (Capillary resistance in geriatrics trial of a microvascular protective agent Endotelon.) Bordeaux Med. 13:903-7, 1990.
  • 43. Lagrue G, et al. Etude des effets des oligomeres du procyanidol sur las resistance capillaire dand l’hypertension arterielle et certaines nephropathies. Sem Hosp Paris 18-25 Septembre, 1981.
  • 44. Beylot C, et al. Essai therapeutique d’un angioprotecteur peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24, 1980.
  • 45. Lesbre FX, et al. Effect de l’Endotelon sur l’indice de fragilite capillaire dan une population specifique: les sujets cirrhotiques. (Effect of endotelon on the capillary fragility index in a specific group: cirrhotic subjects.) Gaz Med France 90:24332-24337, 1983.
  • 46. Sarrat L. Abord therapeutique des troubles fonctionnels des membres inferieurs par un microangioprotecteur l’Endotelon. (Therapeutic approach to functional disorders of lower extremities.) Bordeaux Med, 11:685-8, 1981.
  • 47. Delacroix P. Etude en double aveugle de l’Endotelon dans l’insuffisance veineuse chronique. (Double-blind study of endotelon in chronic venous insufficiency.) Ther. La Revue de Medecine 31:1793-1802, 1981.
  • 48. Thebault J, et al. Etude de l’Endotelon dand les manifestations fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une etude en double aveugle portant sur 92 patients. (Study of endotelon in functional manifestations of peripheral venous insufficiency. Results of a double-blind study on 92 patients.) Gazette Medicale (Montr) 92:12, 1985.
  • 49. Wegrowski J, et al. The effect of procyanidolic oligomers on the composition of normal and hypercholesterolemic rabbit aortas. Biochem Pharmacol 33:3491-7, 1984.
  • 50. Chang WC, et al. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty Acids, 38:181-8, 1989.
  • 51. Masquelier, J. pycnogenol: recent advances in the therapeutical activity of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant Research and Journal of Natural Products, July 1980 pp. 243-256.
  • 52. Henning B, et al. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
  • 53. Fitzpatrick DF, et al. Endothelium-dependant vascular effects of french maritime pine bark extract. J Cardiovas Pharmacol 32:505-515, 1998.
  • 54. Gazave JM. “Notions recentes sur les capillaires” unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
  • 55. Ruf JC. Wine and polyphenols related to platelet aggregation and atherothrombosis. Office International Vigne et du Vin, Nutrition and Health Unit, Paris France; Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131), 1999.
  • 56. Blazso G, et al. M. Oedema-inhibiting effect of procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
  • 57. Tayau MF, et al. Action du leucocyanidol sur l’hyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
  • 58. Lamy M. Utilization des oligomeres procyanidoliques en gynecologie. Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
  • 59. Henriet J. Venous and lymphatic insufficiency 4729 patients receiving hormone therapy and procyanidin oligomers. Phlebologie 46:313-25, 1993.
  • 60. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
  • 61. Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated with (+) -catechin becomes resistant to the action of mammalian collagenase.” Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
  • 62. Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des oligomeres procyanidoliques sur le lathyrisme experimental chez le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
  • 63. Corbe C, et al. Light vision and chorioretinal circulation. Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988.
  • 64. Boissin JP, et al. Chorioretinal circulation and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4, 177-9, 1988.
  • 65. Proto F, et al. Electrophysical study of vitis vinifera procyanoside oligomers effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93, 1988.
  • 66. Saracco, JB, et al. Etude d l’Endotelon en opthalmologie. Gaz Med de France, 88:2035-2038, 1981.
  • 67. Scharrer A, et al. Anthocyanosides in the treatment of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
  • 68. Corbe C, et al. Microangiopathy of the retina. J. Fr. Opthalmol, 11:453, 1988.
  • 69. Verin MM, et al. Retinopathies et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
  • 70. Soyeux A, et al. Endotelon, diabetique et hemorhelogie. (Diabetic retinopathy and hemorheology.) Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
  • 71. Froantin M. Les oligomeres procyanidoliques dans le traitement de la fragilite capillaire et de la retinopathie chez les diabetiques. A propos de 26 cas. (Procyanidolic oligomers in the treatment of capillary fragility and retinopathy in diabetics.) Med Int 16:432-434, 1981.
  • 72. Arne JL. Contribution a l’etude des oligomeres procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
  • 73. Baruch J. Effect of Endotelon in postsurgical edema. Results of a double-blind study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5, 1984.
  • 74. Rao CN, et al. Influence of bioflavonoids on the collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
  • 75. Gabor, M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 9:355-374, 1972.
  • 76. Havsteen, B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
  • 77. Reimann HJ, et al. Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formation by (+)-cate-chin, an inhibitor of specific histidine decarboxylase in vitro. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger., 1977.
  • 78. Masquelier J. Action protectrice du vin sur l’ulcere gastrique. Resultats, p. 61.
  • 79. Amella, M., et al. Inhibition of mast cell histamine release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
  • 80. Shaw, R. How pycnogenol Helps Sports People (Australia).
  • 81. Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums Cosmet Arom 95:89-97, 1990.
  • 82. Pecking A, et al. Oligomeric proanthocyanidins (Endotelons) in the treatment of post therapeutic lymphedema of the upper limbs. Association de Lymphologie de Lange Francaise Hospital Saint-Louis, Paris 69-73, 1989.
  • 83. Laparra J, Michaud J, Masquelier J. Action des oligomeres procyanidoliques sur le cobaye carence en vitamine c. Travaux Originaux, Laboratoire de Matiere Medicale, Faculte de Phamacie de Bordeaux, University of Bordeaux, 1979.
  • 84. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation de l’acide ascorbique par les ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
  • 85. Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4) 1951. pp.304-306
  • 86. Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G., Mishioka, I. “Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull. 33(11)1985. 5079-5082.
  • 87. Reiman, HJ, et al. Histamine and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase in vitro. Dirkhauser Verlag, Vol 7/1, 1977.
  • 88. Pariente J. Post-traumatic edemas in sports: a controlled test of endotelon. Gaz Med France 90:231-6, 1983.
  • 89. Masquelier J, et al. Flavonoides et pycnogenols. Int J Vit Nut Res (49)3:307-311, 1979.
  • 90. Yu C, et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol. 25(2):135-9, 1987.
  • 91. Pantaleoni GC, et al. Univerisity of Aquila Pharmacol-Toxicologica Report, 1971.
  • 92. Laparra J, et al. Etude pharmacocinetique des oligomers procyandoliques totaux du raisin (endotelon), Acta Therapeutica, 4:233, 1978.
  • 93. Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow cells of the mouse with pycnogenol. Cytotest Cell Research GmbH & Co., projects 143010, 143021; Feb 1989.
  • 94. Acute and chronic toxicity tests. International Bio-Research, Inc. Hanover, Germany, 1967-1971.
  • 95. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content in vegetable extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
  • 96. The International Nutrition Company Special Report, Pine vs. Pine Comparative Analysis between Masquelier's Original Pine Bark OPCs and another leading brand pine bark extract, Oc. 1998. PhytoChem Technologies, Inc., Chelmsford, Massachusetts, Ju. 1998. The International Nutrition Company Special Report, Masquelier's Original OPCs and ten grape seed extracts; an independent, reproducible state-of-the-art comparative analysis, No. 1997.
  • 97. Feine-Haake, G. A new therapy for venous diseases. Zeitschrift fur Allgemeinmedizin 839 (June 30, 1975).
  • 98. Gabor, Miklos, Razga, pycnogenol inhibits inflammation in a dose-dependant manner. Acta. Physiol. Hung. 77:197-207 (1991).
  • 99. Dartenus, et al. Bordeaux Med. 13:903 (1980).
  • 100. Biard, L. Evaluation d’une nouvelle therapeutique par la mesure de la resistance capillaire conjuctivale. Medicin Praticienne. 786, 62-66 (1980).
  • 101. Baracco, et al. Gaz Med. de France 88:2035 (1981).
  • 102. Cahn J, et al. Etude de L'administration d'oligomeres procyanidoliques chez le rat. (Administration of procyanidolic oligomers in rats. Observed effects on changes in the permeability of the blood brain barrier.) Semaine des Hopitaux 59:2031-4, 1983.
  • 103. Rohdewald, P. pycnogenol. Vol 7 of Flavonoids in Health and Disease, edited by C. Rice-Evans and L. Packer. New York: Marcel Dekker Inc., 1998.
  • 104. Meunier MT, et al. Activite antiradicalaire d'oligomeres procyanidolique et d'anthocyanosides vis-a-vis de l'anion superoxyde et vis-a-vis del la lipoperoxydation. (Free-radical scavenger activity of procyanthocyanidolic oligomers and anthocyanosides with respect to superoxide and lipid peroxidation.) Plant Med Phytother 23(4):267-274, 1989.
  • 105. Dubos, G., et al. Evolution de la resistance capillaire, spontanement ou artificiellement diminuee par l'action d'une substance capillaro-toxique chez des personnes agees. La Revue de la Geriatrie, Tome 5, no. 6, Sept. 1980.
  • 106. Kidd, P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999 Jun;4(3):144-61.
  • 107. Crook, T.H. The PS Factor: the key to peak mental performance for life. Mind Pub. Inc., 1999.
  • 108. Kidd, P.M. Phosphatidylserine (PS): A Remarkable Brain Cell Nutrient, Lucas Meyer, Inc. Third Edition April 1998.
  • 109. Klinkhammer P, et al. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's disease. Dementia. 1990;1(4):197-201.
  • 110. Kidd, P.M. Phosphatidylserine: the nutrient that accelerates all brain functions and counters Alzheimer’s disease: Keats Pub. 1998.
  • 111. Kidd, P.M. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999 Jun;4(3):144-61.
  • 112. Kidd, P.M. Phosphatidylserine (PS): A Remarkable Brain Cell Nutrient, Lucas Meyer, Inc. Third Edition April 1998.
  • 113. O'Brien, C., Answers to ADD, Vitamin Retailer, March 2002.
  • 114. Cenacchi T., et al. Cognitive decline in the elderly: A double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging, 5: 123–133, 1993.
  • 115. Maggioni M., Picotti GB, Bondiolotti GP et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders. Acta Psychiatr Scand. 81: 265–270, 1990.
  • 116. Brambilla, F., Maggioni, M., Panerai, A.E., et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients—effects of phosphatidylserine therapy. Neuropsychobiology, 34: 18–21, 1996.
  • 117. Monteleone P., Maj M., Beinat L., Natale M., Kemali, D. Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm, 43: 385–388, 1992.
  • 118. Heiss W.D., et al. Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease. Ann N Y Acad Sci 1993 Sep 24;695:327-31.
  • 119. Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein, B., Mistlberger, G. Double-blind study with phosphatidylserine (PS) in parkinsonian patients with senile dementia of Alzheimer’s type (SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
  • 120. Fernholz KM, Seifert JG, Bacharach DW, Burke ER, Gazal O: The Effects of Phosphatidyl Serine on Markers of Muscular Stress in Endurance Runners. Med Sci Sports Exerc 2000, 32(5):S321.
  • 121. Fahey TD, et al. The Hormonal and Perceptive Effects of Phosphatidylserine Administration During Two Weeks of Weight Training-Induced Over-Training. Biol Sport 1998, 15(2):135-144.
  • 122. Crook, TH, et al. Effects of Phosphatidylserine in Alzheimer's Disease. Psychopharmacol Bull 1992;28(1):61-66.
  • 123. Engel R.R., Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 1992 Jun;2(2):149-55.
  • 124. Monteleone P., et al. Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans. Neuroendocrinology 1990 Sep;52(3):243-8.
  • 125. Benton D, et al. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci 2001;4(3):169-78.
  • 126. Crook, TH. Treatment of Age-Related Cognitive Decline: Effects of Phosphatidylserine in: RM Klatz, et al. Anti-Aging Medical Therapeutics, Vol II, 1998:20-29.
  • 127. Vannucchi MG, et al. Effect of Phosphatidylserine on Acetylcholine Release and Content in Cortical Slices From Aging Rats. Neurobiol Aging 1987, 8(5), 403-407.
  • 128. Vannucchi, M.G., Casamenti, F., Pepeu, G. Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by Phosphatidylserine. J. Neurochem 1990, 55, 819-25.
  • 129. Pepeu, G., Giovanelli, L., Giovannini, M.G., Pedata, F. Effects of Phosphatidylserine on cortical acetylcholine release and calcium uptake in adult and aging rats. In Phospholipid research and the nervous system. Biochemical and molecular pharmacology. Horrocks, L.A., Freysz, L., Toffano, G. (Eds), Liviana Press, Padova, 1986, 265-271.
  • 130. Casamenti, F., Mantovani, P., Amaducci, L., Pepeu, G. Effect of phosphatidylserine on acetylcholine output from the cerebral cortex of the rat. J. Neurochem 1979, 32, 529-533.
  • 131. Casamenti, F., Scali, C., Pepeu, G. Phosphatidylserine reverses the age-dependent decrease in cortical acetylcholine release: a microdialysis study, Eur. J. Pharmacol 1991, 194, 11-16.
  • 132. Pedata, F., Giovannelli, L., Spignoli, G., Giovannini, M.G., Pepeu, G. Phosphatidylserine increases acetylcholine release from cortical slices in aged rats. Neurobiol Aging 1985, 6, 337-339.
  • 133. Mazzari S, Battistella, A. Phosphatidylserine effects on dopamine release from striatum synaptosomes. In: Multidisciplinary Approach to Brain Development. Benedetta, C., Balazs, R., Gombos, G., Porcellani, G. (Eds.). Elsevier/North Holland, Amsterdam, 1980, 569-570.
  • 134. Monteleone, P., Beinat, L., Tanzillo, C., Maj, M., Kemali, D. Effects of Phosphatidylserine on the Neuroendocrine Response to Physical Stress in Humans.Neuroendocrinology 1990, 52, 243-248.
  • 135. Hamm, M. Ernährungswissenschaftliche Stellungnahme zur Veränderung der nutritiven Versorgung mit Phosphatidylserin (Nutritional-scientific statement on the change of nutritive provision with phosphatidylserine), 2002.
  • 136. Calderoni, G., Aporti, F., Bellini, F., Sonetti, A.C., Rubini, R., Telato, S., Xu, C., Canotti, A., Toffano, G. Phospholipids as pharmacological tools in the aging brain. In: Horrocks, L.A., Kanfer, J.N., Porcellati, G. (Eds). Phospholipids in the nervous system,Vol II, Physiological roles. Raven Press, New York, 1985, 11-19.
  • 137. Kaibuchi, K., Takay, Y., Nishizuka, Y. Cooperative roles of various membrane phospholipids in the activation of calcium-activated, phospholipid-dependent protein kinase. J. Biol. Chem. 1981, 256, 7146-7149.
  • 138. Raese, J., Patrick, R.L., Barchas, J.D. Phospholipid-induced activation of tyrosine hydroxylase from rat brain striatal synaptosomes. Biochem Pharmacol 1976, 25, 2245-2250.
  • 139. Gindin J, et al. Effect of Soy Lecithin Phosphatidylserine (PS) Treatment on Daily Functioning and Self-Reported General Condition in Patients with Alzheimer's Disease, The Geriatric Institute of Education and Research Kaplan Medical Centre, Rehovot, and Hadassah Medical School, Hebrew University of Jerusalem, Israel (1990).
  • 140. Suzuki, S., Yamatoya, H., Sakai, M., Kataoka, A., Furushiro, M., Kudo, S. Oral Administration of Soybean Lecithin Transphosphatidylated Phosphatidylserine Improves Memory Impairment in Aged Rats. J. Nutr. 2001, 131, 2951-2956.
  • 141. Blokland, A., Honig, W., Brouns, F., Jolles, J. Cognition-enhancing properties of subchronic phosphatidylserine (PS) treatment in middle-aged rats: comparison of bovine cortex with egg PS and soybean PS. Nutrition 1999, 15, 778-783.
  • 142. Fritz, B. Phosphatidylserine: Have we found a Medically Proven Cortisol Antagonist at Last? IM February 1996, 74-75.
  • 143. Fritz, B. Phosphatidylserine: Can this natural supplement reduce cortisol elevation from workouts? Muscle & Fitness,October 1996, 98-100.
  • 144. Burke, E.R., Fahey, T.D. Phosphatidylserine (PS): Promise for Athletic Performance. Keats Pub. 1998,New Canaan, Connecticut, USA, ISBN: 0-87983-979-1.
  • 145. Burke, E.R. PS: An Answer To Intense Training.Nutrition Science News 1998, 3, 252-253.
  • 146. Reimann HJ, et al. Histamine and acute hemorrhagic lesions in rat gastric mucosa: Prevention of stress ulcer by catechin. Agents Actions 7(1):6972, 1977.
  • 147. Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., Schatzberg, F.A. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. Journal of the Amer Med Assoc, 278 (16):1327-32, 1997.
  • 148. Waagepetersen, H.S., Sonnewald, U., Schousboe, A. The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem, 73:1335–42, 1999.
  • 149. Goddard, A.W., Mason, G.F., Almai, A., Rothman, D.L., Behar, K.L., Petroff, O.A.C., Charney, D.S., Krystal, J.H. Reductions in occipital cortex gaba levels in panic disorder detected with h-magnetic resonance spectroscopy. Arch Gen Psychiatry, 58:556-561, 2001.
  • 150. Cavagnini, F., et al. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinol, 93:149–54, 1980.
  • 151. Bhagavan, H.N., et al. The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics, 1975;55: 437-41.
  • 152. ___. Along with riboflavin, vitamin B-6 deficiency has a primary role in the cause of emotional disorder. British Journal of Psychiatry, 141(1982):271-272.
  • 153. ___. Current data suggest that as many as 20 percent of medically cleared population of outpatient depressives may suffer from a vitamin B-6 deficit. The authors point out that nutrition, diet and vitamin levels have received very little attention in the psychiatric literature. Biological Psychiatry, 9:4 (1984):613-6.
  • 154. ___. Does depressive illness cause vitamin B-6 inadequacy, or vice-versa? Nut Rep Int, 27 (Apr. 1993):867-873.
  • 155. Martineau, J., et al. Vit. B6, magnesium, and combined B6-Mg: therapeutic effects. Bio Psy, 20:467-78, 1985.
  • 156. Dolphin, et al. (eds). Vitamin B6: pyridoxal phosphate. John Wiley & Sons, 1986, chapt. 17.
  • 157. ___. Inadequate intake of vitamins, particularly B-1, can result in mental illness. Clin. Neuro, 8 (Jul.--Sep. 1985):286-293.
  • 158. ___. Carpal tunnel syndrome treated with riboflavin and pyridoxine. Proceedings of the Nat. Acad. of Sc. 81 (Nov. 1984):7076-8.
  • 159. Bekaroglu, M., Aslan, Y., Gedik, Y., Deger, O., et al. Relationships between serum free fatty acids and zinc, and attention deficit disorder: a research note. J. Child Psychol. Psychiatry 1996 Fed; 37 (2):225-7.
  • 160. Koenig, W., et al. C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men. Circulation. 1999;99:237-242.
  • 161. Bisoendial, R.J., et al. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J (2010) 31 (17): 2087-2091.
  • 162. Ignarro, L.J., Ignarro, S.W., Palinski, W. of UCLA; Nigris, D.F., Sica, G. Napoli, C of the University of Naples; Lerman, L., Lerman, A of the Mayo Clinic. Vitamins may protect against heart disease. The National Institutes of Health and the Mayo Foundation supported the research, UCLA public release, 15-Jan-2003.
  • 163. Kiechl S., et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation. 2001 Feb 27;103(8):1064-70.
  • 164. Meir J., et al. Vitamin E Consumption and the Risk of Coronary Disease in Women. N Engl J Med 1993; 328:1444-1449.
  • 165. Spartera, Carlo, Report, Univ. Aquila, June 16, 1989; as cited in ref. 8, above.
  • 166. Crook TH, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991; 41(5):644-9.
  • 167. Kim HY, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine inantiapoptotic effect. J Biol Chem 2000; 275(45):35215-23.
  • 168. Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, Lerer B. An open trial of plant-source derived phosphatidylserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci. 2000;37(4):302-7.
  • 169. Garcia MC, Ward G, Ma YC, Salem N, Kim HY. Effect of docosahexaenoic acid on the synthesis of phosphatidylserine in rat brain microsomes and C6 glioma cells. J Neurochem 1998; 70:24-30.
  • 170. Breggin P.R., Director, Int Cntr for the Study of Psychiatry and Psychology; Testimony Before the Subcommittee on Oversight and Investigations Committee on Education and the Workforce U.S. House of Representatives, September 29, 2000.
  • 171. Breggin, P.R., Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action, International Journal of Risk and Safety in Medicine, 12, 3-35, 1999.
  • 172. Lambert, N., Stimulant treatment as a risk factor for nicotine use and substance abuse, Program and Abstracts, 191-8, 1998. NIH Consensus Development Conference Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. November 16-18, 1998. William H. Natcher Conference Center. National Institutes of Health. Bethesda, Maryland.
  • 173. American Academy of Pediatrics, Practice guideline: Diagnosis and evaluation of a child with attention-deficit/hyperactivity disorder, Pediatrics, 105, 1158-70, 2000.
  • 174. Hallowell, E.M., Ratey, J.J., Driven to Distraction: Recognizing and Coping With Attention Deficit Disorder, Simon & Schuster, 1995.
  • 175. Campbell, L.R., et al. Management of Attention Deficit Hyperactivity Disorder: A Continuing Dilemma for Physicians and Educators, Clinical Pediatrics, March, 1990, 29: 191-3.
  • 176. Balch, J.F., The Super Antioxidants - Why They Will Change The Face of Healthcare in the 21st Century, M. Evans and Company, Inc., 1998.
  • 177. Weintraub, S., Natural Treatments for ADD and Hyperactivity, Woodland Pub., 1997.
  • 178. Diller, L.H., Running On Ritalin: A Physician Reflects on Children, Society, and Performance in a Pill, Bantam Books, 1998, 42-43.
  • 179. Reichenberg-Ullman, J., Ullman, R., Ritalin Free Kids: Safe and Effective Homeopathic Medicine for ADD and Other Behavioral and Learning Problems, Prima Health Pub., 1996.
  • 180. Ritalin Finding Its Way Into the Schoolyard, Seattle Times, February 9, 1996.
  • 181. A Risky Rx for Fun, Newsweek, October 30, 1995, 74.
  • 182. Adesman, A.R., Wender, E.H. Helping the Hyperactive Child, Patient Care, March 30, 1992, 96-116.
  • 183. Wender, P.H., Attention Deficit Disorder in Adults, New York/Oxford: Oxford University Press, 1995, 166.
  • 184. Swanson, J.M., et al., Effect of Stimulant Medication on Children with Attention Deficit Disorder: A Review of Reviews, Exceptional Children, 60, 1993: 154-162.
  • 185. Vogel, J., A Stress Test for Children; Is Your 'Problem Child's' Problem Nutrition?, Keats Pub., 1983.
  • 186. Langseth, L., Dowd, J., Glucose tolerance and hyperkinesis, Food and Cosmetic Toxicology, 16 August 1977.
  • 187. Monkeberg, F., Schrimshaw, N.S., Gordon, J.E., et al., Effect of early marasmic malnutrition on subsequent physical and psychological development, Malnutrition, Learning and Behavior, Cambridge, Mass.: MIT Press, 1968.
  • 188. Crook, W.G. Can a What a Child Eats Make Him Dull, Stupid or Hyperactive?, Journal of Learning Disabilities, 13:53-58, 1980.
  • 189. Egger, J., et al. Controlled Trial of oligoantigenic treatment in the hyperkinetic syndrome, Lancet, 1985 Mar 9: 540-5.
  • 190. Kidd, P. Phospholipids: life's building blocks. Vitamin Retailer, Oct. 2002.
  • 191. Benton D, et al. The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor. Nutr Neurosci 2001;4(3):169-78.
  • 192. Kidd, P., Total Health 2002;24: Resource Guide, May-June.
  • 193. ___. High calorie diets with disproportionately low intakes of vitamins and minerals may be the source of widespread marginal malnutrition. Journ of the Amer Col of Nut, 7 (1988):61-67.
  • 194. Wender, E.H., Solanto, M.V., Effects of sugar on aggressive and inattentive behavior in children with attention deficit disorder with hyperactivity and normal children. Pediatrics, 1991 Nov; 88 (5): 960-6.
  • 195. Kaneko, M., et al., Hypothalamic-putuitary-adrenal axis function in children with attention deficit hyperactivity disorder. The Journal of Autism and Developmental Disorders, 1993 Mar; 23 (1): 59-65.
  • 196. Vatz, R.E., professor at Towson State University, and Weinberg, L.S., of the University of Pittsburg, Attention Deficit Delirium, Wall Street Journal, July 27, 1994.
  • 197. Physicians Desk Reference® (PDR®), 53rd Edition, Medical Economics Company.
  • 198. Baruchin, A. "Attention deficits that may linger well past childhood," New York Times, 3/12/08.
  • 199. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, 1994.
  • 200. Werbach MR, et al. Botanical influences on illness: A sourcebook of clinical research, Third Line Press, CA, 1994.
  • 201. Schultz V, et al. Rational Phytotherapy: a physician's guide to herbal medicine, 4th ed. Berlin, 2001.
  • 202. Packer L, et al. Antioxidant Food Supplements in Human Health, Academic Press, CA, 1999.
  • 203. Lincoln J, et al. Nitric Oxide in Health and Disease, Cambridge University Press, UK, 1997.
  • 204. Moncada S, et al. Nitric Oxide and the Cell: proliferation, differentiation and death, Princeton University Press, NJ, 1998.
  • 205. Amsellem, et al. Endotelon dans le traitement des troubles veino-lymphatiques dy syndrome premenstrual. Etude multicentrique sur 165 patientes. (Endotelon in the treatment of venolymphatic problems in premenstrual syndrome, a multicentered study on 165 patients.) Tempo Medical November:282, 1987.
  • 206. Ikemoto A, Kobayashi T, Watanabe S, Okuyama H. Neurite outgrowth induced by NGF is enhanced by added DHA, but suppressed by added AA. Neurochem Res 1997; 22:671-678.
  • 207. Ikemoto A, Okuyama H. Phosphatidyl serine is actively recycled only in cells undergoing NGF-induced neuritogenesis. Neurochem Res 2000; 25:293-301.
  • 208. Souci SW, Fachmann E, Kraut H. Food Composition and Nutrition Tables. Medpharm Scientific Pub. Stuttgart, 2014.
  • 209. Crook, TH, et al. The Memory Cure: the safe, scientifically proven breakthrough that can slow, halt, or even reverse age-related memory loss, Simon & Schuster, NY 1998.
  • 210. Talbott, S. The cortisol connection: why stress makes you fat and ruins your health, Hunter House Pub., CA 2002.
  • 211. Kidd, PM. PS (PhosphatidylSerine): Nature's Brain Booster: a vital lipid nutrient for memory, mood and stress, Total Health Communications, 2005.
  • 212. Kidd, PM. The phospholipids as anti-aging nutraceuticals. In, Anti-Aging Medical Therapeutics, Vol IV, ed. Klatz RM and Goldman R. Chicago, IL: American Academy of Anti-Aging Medicine; 282-95, 2000.
  • 213. Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. The effect of soybean-derived phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. Clin Interv Aging. 8:557–563, 2013.
  • 214. Youngjohn JR, Larrabee GJ, Crook TH. First-last names and the grocery list selective reminding test: two computerized measures of everyday veral learning. Archives of Clinical Neuropsychology 6:287-300, 1991.
  • 215. Jager R, Purpura M, Geiss KR, Weib M, Baumeister J, Amatulli F, Schroder L, Herwegen H. The effect of phosphatidylserine on golf performance. Journal of the International Society of Sports Nutrition 2007, 4:23 doi:10.1186/1550-2783-4-23.
  • 216. Starks MA, et al. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008, 5:11.
  • 217. Hirayama S, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet. (2014) Apr;27 Suppl 2:284-91. doi: 10.1111/jhn.12090.
  • 218. Hirayama H, et al. Effect of phosphatidylserine administration on symptoms of attention-deficit/hyperactivity disorder in children. Agro Food Ind. Hi Tech 2006;17:32–36.
  • 219. Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand. 1986 Feb;73(2):136-40.
  • 220. Palmieri G, Palmieri R, Inzoli MR, et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J . 1987;24:73-83.
  • 221. Ransmayr G, Ploerer S, Gerstenbrand F, Bauer G. Double-blind, placebo-controlled trial of phosphatidylserine in patients with arteriosclerotic encephalopathy. Clinical Trials Journal 1987;24:62-72.
  • 222. Amaducci L. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull. 1:130-4, 1988.
  • 223. Crook T, Petrie W, Wells C, et al. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull. 1992;28:61-66.
  • 224. Nerozzi D, Aceti F, Melia E, et al. Phosphatidylserine and memory disorders in the aged [English abstract]. Clin Ther. 120:399-404, 1987.
  • 225. Villardita C, Grioli S, Salmeri G, et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J. 1987;24:84-93.
  • 226. Furushiro M, Suzuki S, et al. Effects of oral administration of soybean lecithin transphosphatidylated phosphatidylserine PS on impaired learning of passive avoidance in mice. Jpn. J. Phamacol. 1997;75:447-450.
  • 227. Sakai M, Yamatoya H, Kudo S. Pharmacological effects of phosphatidylserine synthesized from soybean lecithin on brain functions in rodents. Nutr.Sci.Vitaminol. 1996;42:47-54.
  • 228. Burke R. Phosphatidylserine protects from muscle damage. Nutrition Science News, 2000, 5, 371-372.
  • 229. Masquelier, J. “Les procyanidols du vin leur role dans l’alcolisme.” pp. 88-93.
  • 230. Bombardelli, E. Vitis vinifera L. Fitoterapia, 66:291-317, 1995.
  • 231. Sano M, et al. A controlled trial of selegiline, alpha-tocopherol or both as treatment for alzheimer's disease. N. Engl. J. Med. 1997 Apr:1216-1222.
  • 232. Black P. Psychoneuroimmunology. Brain and immunity. Scientific American 1995 Nov-Dec: 16-25.
  • 233. Fabris N, et al. Neuroimmunomodulations: the state of the art. Ann NY Acad Sci 1994; Vol 741.
  • 234. Jankovic BD, et al. Neuroimmune interactions. Ann NY Acad Sci 1987; Vol 496.
  • 235. Snyder S. Nitric oxide: first in a new class of neurotransmitter. Science 1992 Jul; Vol 253.
  • 236. Streight WJ, et al. The brain's immune system. Sci American 1995 Nov; 273(5):54-56.
  • 237. Koller-Stametz J, et al. Role of nitric oxide in exercise-induced vasodilation in man. Life Sci 62: 1035-1043, 1998
  • 238. Koss MC. Functional role of nitric oxide in regulation of ocular blood flow. Eur J Pharmacol 374: 161-174, 1999.
  • 239. Dorner GT, et al. Nitric oxide regulates retinal vascular tone in man. Am J Physiol Heart Circ Physiol (May 15, 2003). 10.1152/ajpheart.00111.2003.
  • 240. Beal MF. Aging, energy and oxidative stress in neurodegenerative diseases. Ann Neurol 1995 Sept; 38(3):357-68.
  • 241. Palmer AM, et al. Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease. Brain Res 1994; 645:338-47.
  • 242. Steinman L. Autoimmune disease. Sci Amer 1993 Sept;107-14.
  • 243. Fletcher AE. Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and age-related macular degeneration. Ophthalmic Res. 2010;44(3):191-8. doi: 10.1159/000316476. Epub 2010 Sep 9.
  • 244. Fletcher AE, et al. Sunlight exposure, antioxidants, and age-related macular degeneration. Arch Ophthalmol. 2008 Oct;126(10):1396-403. doi: 10.1001/archopht.126.10.1396.
  • 245. Lubica H. Flavonoids in prevention of diseases with respect to modulation of Ca-pump function. Interdiscip Toxicol. 2011 Sep; 4(3): 114–124.
  • 246. Toborek M, et al. Linoleic acid potentiates TNF mediated oxidative stress, disruption of calcium homeostasis and apoptosis of cultured vascular endothelial cells. J Lipid Res 1997 Oct;38(1):2155-67.
  • 247. Chasen Paul J, et al. Methods and compositions for treating attention-deficit/hyperactivity disorder. "A regimen and composition for treating attention deficit/disorder (ADHD) by the use of proanthocyanidin both with and without a heterocyclic anti-depressant, preferably desipramine and a citrus bioflavinoid." U.S. Patent No. 5,719,178, 1998.
  • 248. Stamatovic SM, et al. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol. Sep; 6(3): 179–192, 2008.
  • 249. Saracco and Estachy, oral applications of extracts of proanthocyanidins slow down the progression of the retinopathy disease. Gaz. Med. France, 88: 2035 2038, 1981.
  • 250. Fromantin M. Les Oligomeres Procyanidoliques dans le traitement de la fragilite capillaire et de la Retinopathie chez les diabetiques. Med Int. 16(11), 432-434, 1981.
  • 251. Gabor et al. action of proanthocyanidins in case of diabetic retinopathy as being due to sealing of leaky capillaries. Phlebologie, 22; 178-182, 1993.
  • 252. Kumpulainen JT, et al. Natural Antioxidants and Anticarcinogens in Nutrition, Health and Disease Elsevier: 1999.
  • 253. Rice-Evans CA, et al. Free Rad. Biol. Med. 20:933, 1996.
  • 254. Salah N, et al. Arch. Biochem. Biophys. 322:339, 1995.
  • 255. Buening MK, et al. A.H. Canc. Res. 41:67, 1981.
  • 256. Kolodziej, H, et al. Phytother. Res. 9:410, 1995.
  • 257. Kingsley M, et al. Effects of phosphatidylserine supplementation on exercising humans. Sports Med (2006) 36:657-669.
  • 258. Kingsley M, et al. Effects of phosphatidylserine on exercise capacity during cycling in active males. Medicine and science in sports and exercise. 2006;38:64-71
  • 259. Kingsley M, et al. Effects of phosphatidylserine on oxidative stress following intermittent running. Medicine and science in sports and exercise. 2005;37:1300-1306
  • 260. Bouhamidi R, et al. High protection by grape seed proanthocyanidins (GSPC) of polyunsaturated fatty acids against UV-C induced peroxidation. C R Acad Sci III 321:31-8, 1998.
  • 261. Virgili F, et al. Procyanidins extracted from pine bark protect alphatocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 431:315-8, 1998.
  • 262. Moriconi S, et al. Clinical study on activity of vitis vinifera procyanidolic oligomers on myopic patients retinic sensitivity. Ann Ottal Clin Ocul 114:585-94, 1988.
  • 263. Fusi L, et al. Procyanidolic oligomers effects in patients working at a display unit. Ann Ottal Clin Ocul 116:575-84, 1990.
  • 264. Putter M, et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95:155-61, 1999
  • 265. Fitzpatrick DF, et al. Endothelium-dependent vascular effects of pycnogenol. J Cardiovasc Pharmacol 32:509-15, 1998.
  • 266. Drubaix I, et al. Synthesis of glycoconjugates by human diseased veins: modulation by procyanidolic oligomers. Intl J Experiment Pathol 78:117-21, 1997.
  • 267. Gavignet C, et al. Study of the influence of procyanidolic oligomers on cultured mesenchymal cells. I - Effect on the attachment, the proliferation and detachment of cells. Path Biol 37:746-53, 1989.
  • 268. Robert L, et al. Action of procyanidolic oligomers on vascular permeability. A study by quantitative morphology.Path Biol:6, 1990.
  • 269. Doutremepuich J, et al. Effect of Endotelon (procyanidolic oligomers) on experimental acute lymphedema of the rat hindlimb. Lymphology 24:135-9, 1991.
  • 270. Mollman H, et al. A naturally occurring bioflavonoid complex with capillary protective action. Therapiewoche 33:4967, 1983.
  • 271. Bagchi D, et al. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Res Commun Mol Pathol Pharmacol 95:179-89, 1997.
  • 272. Bagchi D, et al. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen Pharmacol 30:771-6, 1998.
  • 273. Facino RM, et al. Free radicals scavenging action and antienzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung 44:592-601, 1994.
  • 274. Facino RM, et al. Sparing effect of procyanidins from Vitis vinifera on vitamin E: in vitro studies. Planta Med 64:343-347, 1998.
  • 275. Facino RM, et al. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 62:495-502, 1996.
  • 276. Simonetti P, et al. Procyanidins from Vitis vinifera seeds: in vivo effects on oxidative stress. J Agric Food Chem 50:6217-6221, 2002.
  • 277. Preuss HG, et al. Effects of niacin-bound chromium and grape seed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study. J Med 31:227-246, 2000.
  • 278. Bayeta E, et al. Pycnogenol inhibits generation of inflammatory mediators in macrophages. Nutr Res 20:249-259, 2000.
  • 279. Blazso G, et al. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 52:380-382, 1997.
  • 280. Li WG, et al. Antiinflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin 22:1117-1120, 2001.
  • 281. Liviero L, et al. Antimutagenic activity of procyanidins from Vitis vinifera. Fitoterapia 65:203-209, 1994.
  • 282. Noda Y, et al. Hydroxyl and superoxide anion radical scavenging activities of natural source antioxidants using the computerized JES-FR30 ESR spectrometer system. Biochem Mol Biol Int 42:35-44, 1997.
  • 283. Sato M, et al. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann N Y Acad Sci 957:122-135, 2002.
  • 284. Natella F, et al. Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans. J Agric Food Chem 50:7720-7725, 2002.
  • 285. Hosseini S, et al. Pycnogenol in the management of asthma. J Med Food 4:201-209, 2001.
  • 286. Putter M, et al. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95:155-161, 1999.
  • 287. Yamakoshi J, et al. Safety evaluation of proanthocyanidin-rich extract from grape seeds. Food Chem Toxicol 40:599-607, 2002.
  • 288. Chang WC, et al. Inhibition of platelet aggregation and arachidonate metabolism in platelets by procyanidins. Prostaglandins Leukot Essent Fatty Acids 38:181-188, 1989.
  • 299. Cohen, SA, et al. Age-related alterations of NMDA-receptor properties in the mouse forebrain: partial restoration by chronic phosphatidylserine treatment. Brain Research 1992, 584, 174-180.
  • 290. Nair MP, et al. Grape seed extract proanthocyanidins downregulate HIV-1 entry coreceptors, CCR2b, CCR3, and CCR5 gene expression by normal peripheral blood mononuclear cells. Biol Res 35:421-431, 2002.
  • 291. Pepeu G, et al. A review of phosphatidylserine pharmacological and clinical effects. Is phosphatidylserine a drug for the ageing brain? Pharmacol Res. 1996;33:73-80.
  • 292. Packer L, et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 27:704-24, 1999.
  • 293. Weingest K, et al. Procyanidine aus Früchten Zur Kenntnis der Proanthocyanidine. Liebigs A Chem 711, 184-204, 1968.
  • 294. Facino RM, et al. Diet enriched with procyanidins enhances antioxidant activity and reduces myocardial post-ischaemic damage in rats. Life Sci 64:627-42, 1999.
  • 295. Hertog MG, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007-11, 1993.
  • 296. Constant J. Alcohol, ischemic heart disease, and the French paradox. Coronary Artery Disease 8:645-9, 1997.
  • 297. Gabor MR. Vascular effects of oxygen-derived free radicals. Biology & Med 4:107-120, 1988.
  • 298. Cheshier JE, et al. Immunomodulation by pycnogenol in retrovirus-infected or ethanol-fed mice. Life Sci 58:87-96, 1996.
  • 299. Bagchi M, et al. Smokeless tobacco, oxidative stress, apoptosis, and antioxidants in human oral keratinocytes. Free Radic Biol Med 26:992-1000, 1999.
  • 300. Nelson A, et al. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical induced DNA damage. Drug Devel Industr Pharm 24:139-44, 1998.
  • 301. Virgili F, et al. Procyanidins extracted from Pinus maritima: scavengers of free radical species and modulators of nitrogen monoxide metabolism in activated murine RAW 264.7 macrophages. Free Radical Biology & Medicine 24:1120-9, 1998.
  • 302. Fitzpatrick DF, et al. Isolation and characterization of endothelium dependent vasorelaxing compounds from grape seeds. J Agric Food Chem 48:6384-6390, 2000.
  • 303. Saito M, et al. Antiulcer activity of grape seed extract and procyanidins. J Agricult Food Chem 46:1460-64, 1998.
  • 304. S Iravani1, et al. Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract. Res Pharm Sci. Jan-Jun; 6(1): 1–11, 2011.
  • 305. Cho KJ, et al. Effect of proanthocyanidins extracted from the bark of Pinus maritime on proinflammatory cytokine interleukin-1 production in lipopolysaccharide-stimulated RAW 264.7. Toxicol Appl Pharmacol. 168:64–71, 2000.
  • 306. Park YC, et al. Activity of monomeric, dimeric, and trimeric flavanols on NO production, TNFalpha secretion, and NF-kappaB-dependent gene expression in RAW 264.7 macrophages. FEBS Lett. 465:93–97, 2004.
  • 307. Banerjee B, et al. Beneficial effects of a novel IH636 grape seed proanthocyanidin extract in the treatment of chronic pancreatitis. Digestion 63:203-206, 2001.
  • 308. Liu FJ, et al. Pycnogenol enhances immune and haemopoietic functions in senescence-accelerated mice. Cell Mol Life Sci 54:1168-72, 1998.
  • 309. Bagchi D, et al. Protection against drug- and chemical-induced multi-organ toxicity by a novel IH636 grape seed proanthocyanidin extract. Drugs Exp Clin Res 27:3-15, 2001.
  • 310. Ray SD, et al. In vivo protection of DNA damage associated apoptotic and necrotic cell deaths during acetaminopheninduced nephrotoxicity, amiodarone-induced lung toxicity, and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. Res Commun Mol Pathol Pharmacol 107:137-166, 2000.
  • 311. Stefanovic V, et al. Reversal of experimental myoglobinuric acute renal failure with bioflavonoids from seeds of grape. Ren Fail 22:255-266, 2000.
  • 312. Witte MB, et al. Enhancement of fibroblast collagen synthesis by nitric oxide. Nitric Oxide 4:572-582, 2000.
  • 313. Stallmeyer B, et al. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely inhibits wound reepithelialization. J Invest Dermatol 113:1090-1098, 1999.
  • 314. Frank S, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 13:2002-2014, 1999.
  • 315. Most D, et al. Characterization of incisional wound healing in inducible nitric oxide synthase knockout mice. Surgery 132:866-876, 2002.
  • 316. Khanna S, et al. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 31:38-42, 2001.
  • 317. Khanna S, et al. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic Biol Med 33:1089-1096, 2002.
  • 318. Howard J. "Americans devote more than 10 hours a day to screen time, and growing," CNN updated Jul 29, 2016; reporting on Nielsen company audience report Q1 2016 dated Jun 27, 2016.
  • 319. Beatty S, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 45(2)115–134, 2000.
  • 320. Dillon J, et al. Transmission of light to the aging human retina: possible implications for age related macular degeneration. Exp Eye Res. 79(6)753–759, 2004.
  • 321. Algvere PV, et al. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand. 84(1)4–15, 2006.
  • 322. "Blue light has a dark side. Exposure to blue light at night, emitted by electronics and energy-efficient light bulbs, harmful to your health." Harvard Health Letter, Harvard Health Pub., Harvard Med School. May 2012, updated Sep 2, 2015.
  • 323. Fletcher, AE. Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and age-related macular degeneration. Ophthalmic Res. 2010;44(3):191-8. doi: 10.1159/000316476. Epub Sep 9, 2010.
  • 324. Rose RC, et al. Ocular oxidants and antioxidant protection. Proc Soc Exp Biol Med 217(4):397-407, 1998.
  • 325. Van der Hagen AM, et al. Free radicals and antioxidant supplementation: a review of their roles in age related macular degeneration. J Am Optom Assoc 64:871-78, 1993.
  • 326. Zastrow L, et al. UV, visible and infrared light. Which wavelengths produce oxidative stress in human skin? Hautarzt. 2009 Apr;60(4):310-7. doi: 10.1007/s00105-008-1628-6.
  • 327. Shaw PX, et al. Oxidative stress, innate immunity, and age-related macular degeneration. AIMS Mol Sci. 3(2): 196–221, 2016.
  • 328. Yang H, et al. Protective effect of grape seed extract against oxidative stress-induced cell death in a staurosporine-differentiated retinal ganglion cell line. Curr Eye Res. 2012;37:339–344.
  • 329. Wang H, et al. Oligomeric proanthocyanidin protects retinal ganglion cells against oxidative stress-induced apoptosis. Neural Regen Res. 2013 Sep 5; 8(25): 2317–2326.
  • 330. Zeisel SH. Choline: an essential nutrient for humans. Nutrition. 2000 Jul-Aug;16(7-8):669-71.
  • 331. Blum K, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 2008 Oct;4(5):893-918.
  • 332. Kapur S, et al. Role of the dopaminergic system in depression. Biol Psychiatry. 1992 Jul 1;32(1):1-17.
  • 333. Hochreiter-Hufford AE, et al. Phosphatidylserine receptor BAI1 and apoptotic cells as new promoters of myoblast fusion. Nature. 2013;497:263-267
  • 334. Joy JM, et al. Phosphatidic acid enhances mTOR signaling and resistance exercise induced hypertrophy. Nutrition & metabolism. 2014;11:29.
  • 335. Kato-Kataoka A, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. J Clin Biochem Nutr. 2010;47:246-255.
  • 336. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9:570-579
  • 337. Mozzi R, et al. Metabolism and functions of phosphatidylserine in mammalian brain. Neurochem Res. 2003;28:195-214.
  • 338. Yong T, et al. Research on human memory enhancement by phosphatidylserine fortified milk. Chongqing Medicine. 2011;40:3022-3023.

References for BioMor® Curcumin

BioMor® Curcumin is produced using a patented technology that results in up to 800% greater curcumin absorption in humans—and it's faster-acting and longer-lasting—compared to other curcumin extracts. (23)
BioMor Curcumin

Clinically Proven and Patented

Buy Now Call Now
  • 1. Sarker, S.D., et al. “Bioactivity of Turmeric,” Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 2. Shishodia, S., et al. “Curcumin: Getting Back to the Roots,” Ann. N.Y. Acad. Sci.: 1056, 206-217, 2005.
  • 3. Majeed, M., et al. Curcuminoids: antioxidant nutrients. Piscataway, NJ: Nutriscience Pubs., Inc., 1995.
  • 4. Bharat, B.A., et al. “Curcumin--Biological and Medicinal Properties,” Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 5. Atal, C.K., et al. "Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism," American Society for Pharmacology and Experimental Therapeutics: Vol. 232, Issue 1, pp. 258-262, 1985.
  • 6. Kotwal, G.J., et al. Natural Products and Molecular Therapy, First International Conference. New York, NY: Annals of the New York Academy of Sciences, Vol. 1056, 2005.
  • 7. National Institutes of Health. MedlinePlus Herbs and Supplements: "Turmeric (Curcuma longa Linn.) and Curcumin," US Department of Health and Human Services; Natural Standard Research Collaboration: 2008 ed.: nlm.nih.gov
  • 8. Benny, M., et al. Spice India: Vol. 19, No. 9, pp. 11-15, 2006.
  • 9. Antony, B., et al. “Evaluation of a novel bioenhanced curcumin,” Indian Journal of Pharmaceutical Sciences: Jul-Aug, pp. 445-50, 2008
  • 10. “A Pilot Cross-Over Study to evaluate human oral bioavailability of BCM-95, A Novel Bioenhanced Preparation of Curcumin.” Ind J Pharm Sci. 2008;70(4):445-449.
  • 11. Bezerra, D.P., et al. “In vivo growth-inhibition of sarcoma 180 by piplartine and piperine, two alkaloid amides from Piper.” Brazilian journal of medical and biological research: Vol. 39, No. 6, pp. 801-807, 2006.
  • 12. Van Wyk, B.E., et al. Medicinal Plants of the World. Portland OR: Timber Press Inc., 2004.
  • 13. Duke, J.A., et al. CRC Handbook of Medicinal Spices. Boca Raton, FL: CRC Press, 2003.
  • 14. Cronin, J.R. “Curcumin: Old spice is a new medicine.” Journal of Alternative & Complementary Therapies: Feb. 2003, pp. 34-38.
  • 15. Cheng, A.L., et al. “Phase I clinical trial of curcumin, a chemoprotective agent, in patients with high-risk or pre-malignant lesions.” Anti-cancer Res. 2001; July-Aug 21:2895-2900.
  • 16. Anand, P., et al. “Bioavailability of Curcumin: Problems and Promises,” Mol. Pharmaceutics: 2007, 4(6), pp. 807-818. (Cytokine Research Laboratory and Pharmaceutical Development Center, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.)
  • 17. Antony, B., et al. “A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin,” Indian J. Pharm. Sci.: 2008, 70(4), pp. 445-450.
  • 18. Piyachaturawat P., et al. “Acute and subacute toxicity of piperine in mice, rats and hamsters,” Toxicol Lett 1983;16:351-9.
  • 19. Daware, M.B., et al. “Reproductive toxicity of piperine in swiss albino mice,” Planta Med 2000;66:231-6.
  • 20. Panda S., et al. “Piperine lowers the serum concentrations of thyroid hormones, glucose and hepatic 5'D activity in adult male mice,” Horm Metab Res 2003;35:523-6.
  • 21. Unchern, S., et al. “Death of cerebellar granule neurons induced by piperine is distinct from that induced by low potassium,” Neurochem Res 1998;23:97-102.
  • 22. Werbach M.R., et al. Botanical Influences on Illness: A Sourcebook of Clinical Research: Second Edition. Tarzana, CA: Third Line Press Inc., 2000.
  • 23. Antony, B. “Composition to Enhance the Bioavailability of Curcumin,” U.S. Patent Nos. 7,736,679, 7,883,728, 7,879,373 (2011).
  • 24. Liva, R. “Toxic Solvent Found in Curcumin Extract,” Integrative Medicine, 9:5 Oct/Nov 2010.
  • 25. Tebbey, P.W., Buttke, T.M. “Molecular basis for the immunosuppressive action of stearic acid on T cells,”Immunology, 70(3): 379–386, Jul 1990.
  • 26. Jones, D.M. “Factors to Consider in Fluid-Bed Processing,” Pharmaceutical Technology, Apr 1985.